Gutiérrez GR, Calixto RY, Pupo BJ, Maceira RL, Tasé VD, Riverón FG

Language: Spanish
References: 10
Page: 273-279
PDF size: 211.84 Kb.

ABSTRACT

Fanconi anemia (FA) is a chromosomal instability syndrome characterized by various dysmorphic features, progressive pancytopenia and predisposition to hematological malignancies. The assay sensitivity to mitomycin C (MMC) provides a unique cell marker for the diagnosis of the disease. In order to introduce this chromosomal breakage test the technique was applied in two samples from a patient with clinical suspicion of AF and a control subject. Peripheral blood samples were cultured by protocols established for cytogenetic studies. Four flasks were prepared for each sample culture. Only sodium chloride was added to one of the flasks (control) and to the remaining flasks increasing concentrations of MMC (50, 150 and 300 nM) were added. Fifty metaphases were analyzed for each bottle. Exposure of lymphocytes from the patient at all concentrations of MMC caused significant differences in the number of cells with chromosome breaks with respect to the same exposure in the control (p ‹ 0.005). Assay success was proved considering that in 300 nM in healthy control only 32 % shows cell breakage. It is interesting to remark that in the patient sample with highest concentration, the presence of two cell lines were observed, one with little or no breakage (38 %) similar to those found in no-F cells and other with multiple breaks (62 %), typical of AF cells. These results indicated the presence of somatic mosaicism in patient´s T lymphocytes. The results obtained confirmed the clinical suspicion that this is an AF patient, due to the hypersensitivity to the action of MMC and the presence of somatic mosaicism in T lymphocytes.

REFERENCES

1. Auerbach AD. Fanconi anemia and its diagnosis. Mutation Research. 2009;668:4-10.

2. Lanneaux J, Poidvin A, Soole F, Leclerc G, Grimaud M, Dalle JH. Fanconi anemia in 2012: diagnosis, pediatric follow-up and treatment. Arch Pediatr. 2012;19(10):1100-9.

3. Castella M, Pujol R, Callén E, Ramírez MJ, Casado JA, Talavera M, et al. Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. J Med Genet. 2011;48(4):242-50.

4. Porto B, Sousa R, Ponte F, Torgal A, Campilho F, Campos A, et al. Fanconi anemia: cytogenetic diagnosis of 40 cases. Acta Med Port. 2011;24(3):405-12.

5. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011;11:467-80.

6. Oostra AB, Nieuwint AWM, Joenje H, de Winter JP. Diagnosis of Fanconi Anemia: Chromosomal Breakage Analysis. Anemia. 2012;2012:238731.

7. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73:391-6.

8. Gregory JJ Jr, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA. 2001;98:2532-7.

9. Pinto F, Leblanc T, Chamousset D, Le Roux G, Brethon B, Cassinat B, et al. Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica. 2009;94(4):487-95.

10. Hamanoue S, Yagasaki H, Tsuruta T, Oda T, Yabe H, Yabe M, et al. Myeloid lineage-selective growth of revertant cells in Fanconi anaemia. Br J Haematol. 2006;132(5):630-5.